Drilldown: Medicines
Use the filters below to narrow your results.
generic:
3-MMC (1) ·
Butylone (1) ·
Cathinone (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Hexedrone (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Pentedrone (1) ·
Rimegepant (1) ·
Rizatriptan (benzoate) (1) ·
Sumatriptan (succinate) (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
starting dose:
None (14) ·
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) ·
Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)
preparations:
None (14) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) ·
Orally disintegrating tablet 75 mg (1) ·
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (14) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 17 results in range #1 to #17.